Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment

Cancer Research

Volumn 74, Issue 24, 2014, Pages 7239-7249

  Cekic, Caglar ^a,b   Linden, Joel ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b BILKENT UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; INTERLEUKIN 7 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; INTERLEUKIN 7 RECEPTOR ALPHA;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BLADDER CARCINOMA; CD8+ T LYMPHOCYTE; CELL DENSITY; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; IN VIVO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; WILD TYPE; ADAPTIVE IMMUNITY; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; INNATE IMMUNITY; METABOLISM; PATHOLOGY; URINARY BLADDER NEOPLASMS;

ADAPTIVE IMMUNITY; ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY; INTERLEUKIN-7 RECEPTOR ALPHA SUBUNIT; MELANOMA; MICE; RECEPTOR, ADENOSINE A2A; TUMOR MICROENVIRONMENT; URINARY BLADDER NEOPLASMS;

EID: 84918545478     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-13-3581     Document Type: Article

References (32)

1. Allard B, Turcotte M, Stagg J. CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J Biomed Biotechnol 2012;2012:485156.
2. Beavis PA, Divisekera U, Paget C, Chow MT, John LB, Devaud C, et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci U S A 2013;110:14711-6.
3. Clayton A, Al-Taei S, Webber J, Mason MD, Tabi Z. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. J Immunol 2011;187:676-83.
4. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204:1257-65.
5. Lappas CM, Rieger JM, Linden J. A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J Immunol 2005;174:1073-80.
6. Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene 2010;29:5346-58.
7. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci U S A 2006;103:13132-7.
8. Waickman AT, Alme A, Senaldi L, Zarek PE, Horton M, Powell JD. Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother 2012;61:917-26.
9. Gao J, Bernatchez C, Sharma P, Radvanyi LG, Hwu P. Advances in the development of cancer immunotherapies. Trends Immunol 2013;34:90-8.
10. Sitkovsky MV, Kjaergaard J, Lukashev D, Ohta A. Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia. Clin Cancer Res 2008;14:5947-52.
11. Cekic C, Sag D, Li Y, Theodorescu D, Strieter R, Linden J. Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol 2012;188:198-205.
12. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009;206:1457-64.
13. Himer L, Csoka B, Selmeczy Z, Koscso B, Pocza T, Pacher P, et al. Adenosine A2A receptor activation protects CD4+ T lymphocytes against activation-induced cell death. FASEB J 2010;24:2631-40.
14. Stagg J, Beavis PA, Divisekera U, Liu MC, Moller A, Darcy PK, et al. CD73-deficient mice are resistant to carcinogenesis. Cancer Res 2012;72:2190-6.
15. Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res 2011;71:2892-900.
16. Wang L, Fan J, Thompson LF, Zhang Y, Shin T, Curiel TJ, et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest 2011;121:2371-82.
17. Yegutkin GG, Marttila-Ichihara F, Karikoski M, Niemela J, Laurila JP, Elima K, et al. Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur J Immunol 2011;41:1231-41.
18. Luo Y, Han R, Evanoff DP, Chen X. Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guerin (BCG)-induced macrophage cytotoxicity against bladder cancer cells. Clin Exp Immunol 2010;160:359-68.
19. Falo LD Jr, Kovacsovics-Bankowski M, Thompson K, Rock KL. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat Med 1995;1:649-53.
20. Chen JF, Huang Z, Ma J, Zhu J, Moratalla R, Standaert D, et al. A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 1999;19:9192-200.
21. Lee PP, Fitzpatrick DR, Beard C, Jessup HK, Lehar S, Makar KW, et al. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 2001;15:763-74.
22. Cekic C, Sag D, Day YJ, Linden J. Extracellular adenosine regulates naive T cell development and peripheral maintenance. J Exp Med 2013;210:2693-706.
23. 2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res 2014;74:7250-59.
24. Huang S, Apasov S, Koshiba M, Sitkovsky M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated inhibition of T-cell activation and expansion. Blood 1997;90:1600-10.
25. Conche C, Boulla G, Trautmann A, Randriamampita C. T cell adhesion primes antigen receptor-induced calcium responses through a transient rise in adenosine 3′,5′-cyclic monophosphate. Immunity 2009;30:33-43.
26. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 2008;7:759-70.
27. Wilson JM, Ross WG, Agbai ON, Frazier R, Figler RA, Rieger J, et al. The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells. J Immunol 2009;182:4616-23.
28. Shrikant P, Mescher MF. Opposing effects of IL-2 in tumor immunotherapy: promoting CD8 T cell growth and inducing apoptosis. J Immunol 2002;169:1753-9.
29. Araki K, Turner AP, Shaffer VO, Gangappa S, Keller SA, Bachmann MF, et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009;460:108-12.
30. Svirshchevskaya EV, Mariotti J, Wright MH, Viskova NY, Telford W, Fowler DH, et al. Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity. BMC Cancer 2008;8:176.
31. Murphree LJ, Sullivan GW, Marshall MA, Linden J. Lipopolysaccharide rapidly modifies adenosine receptor transcripts in murine and human macrophages: role of NF-kappaB in A(2A) adenosine receptor induction. Biochem J 2005;391:575-80.
32. Lin G, Field JJ, Yu JC, Ken R, Neuberg D, Nathan DG, et al. NF-kappaB is activated in CD4 iNKT cells by sickle cell disease and mediates rapid induction of adenosine a receptors. PLoS ONE 2013;8:e74664.